vs

Side-by-side financial comparison of ALPHA & OMEGA SEMICONDUCTOR Ltd (AOSL) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

ALPHA & OMEGA SEMICONDUCTOR Ltd is the larger business by last-quarter revenue ($162.3M vs $117.7M, roughly 1.4× CareDx, Inc.). CareDx, Inc. runs the higher net margin — 2.4% vs -8.2%, a 10.6% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -6.3%). CareDx, Inc. produced more free cash flow last quarter ($514.0K vs $-23.1M). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs 4.0%).

Alpha & Omega Semiconductor Ltd designs, manufactures and markets a broad portfolio of power semiconductors, including power MOSFETs, IGBTs, analog ICs and power management modules. Its products are applied across consumer electronics, industrial equipment, automotive systems, telecom and computing segments, with sales networks covering major global markets.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

AOSL vs CDNA — Head-to-Head

Bigger by revenue
AOSL
AOSL
1.4× larger
AOSL
$162.3M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+45.3% gap
CDNA
39.0%
-6.3%
AOSL
Higher net margin
CDNA
CDNA
10.6% more per $
CDNA
2.4%
-8.2%
AOSL
More free cash flow
CDNA
CDNA
$23.6M more FCF
CDNA
$514.0K
$-23.1M
AOSL
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
4.0%
AOSL

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
AOSL
AOSL
CDNA
CDNA
Revenue
$162.3M
$117.7M
Net Profit
$-13.3M
$2.8M
Gross Margin
21.5%
Operating Margin
-8.4%
1.0%
Net Margin
-8.2%
2.4%
Revenue YoY
-6.3%
39.0%
Net Profit YoY
-101.0%
EPS (diluted)
$-0.45
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOSL
AOSL
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$162.3M
$108.4M
Q3 25
$182.5M
$100.1M
Q2 25
$176.5M
$86.7M
Q1 25
$164.6M
$84.7M
Q4 24
$173.2M
$86.6M
Q3 24
$181.9M
$82.9M
Q2 24
$161.3M
$92.3M
Net Profit
AOSL
AOSL
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$-13.3M
$-4.1M
Q3 25
$-2.1M
$1.7M
Q2 25
$-77.1M
$-8.6M
Q1 25
$-10.8M
$-10.4M
Q4 24
$-6.6M
$87.7M
Q3 24
$-2.5M
$-10.6M
Q2 24
$-2.7M
$-4.6M
Gross Margin
AOSL
AOSL
CDNA
CDNA
Q1 26
Q4 25
21.5%
Q3 25
23.5%
Q2 25
23.4%
Q1 25
21.4%
Q4 24
23.1%
Q3 24
24.5%
Q2 24
25.7%
Operating Margin
AOSL
AOSL
CDNA
CDNA
Q1 26
1.0%
Q4 25
-8.4%
-5.6%
Q3 25
-2.5%
-0.2%
Q2 25
-6.6%
-12.8%
Q1 25
-6.5%
-15.8%
Q4 24
-3.4%
97.5%
Q3 24
-0.1%
-16.6%
Q2 24
-0.9%
-7.9%
Net Margin
AOSL
AOSL
CDNA
CDNA
Q1 26
2.4%
Q4 25
-8.2%
-3.8%
Q3 25
-1.2%
1.7%
Q2 25
-43.7%
-9.9%
Q1 25
-6.6%
-12.2%
Q4 24
-3.8%
101.3%
Q3 24
-1.4%
-12.8%
Q2 24
-1.7%
-5.0%
EPS (diluted)
AOSL
AOSL
CDNA
CDNA
Q1 26
$0.05
Q4 25
$-0.45
$-0.08
Q3 25
$-0.07
$0.03
Q2 25
$-2.61
$-0.16
Q1 25
$-0.37
$-0.19
Q4 24
$-0.23
$1.60
Q3 24
$-0.09
$-0.20
Q2 24
$-0.09
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOSL
AOSL
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$196.3M
$77.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$818.8M
Total Assets
$1.0B
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOSL
AOSL
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$196.3M
$177.2M
Q3 25
$223.5M
$194.2M
Q2 25
$153.1M
$186.3M
Q1 25
$169.4M
$230.9M
Q4 24
$182.6M
$260.7M
Q3 24
$176.0M
$240.9M
Q2 24
$175.1M
$228.9M
Total Debt
AOSL
AOSL
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
$14.9M
Q1 25
Q4 24
Q3 24
$0
Q2 24
$26.7M
$0
Stockholders' Equity
AOSL
AOSL
CDNA
CDNA
Q1 26
Q4 25
$818.8M
$303.1M
Q3 25
$834.1M
$311.1M
Q2 25
$822.3M
$327.4M
Q1 25
$886.3M
$379.3M
Q4 24
$902.6M
$378.4M
Q3 24
$895.3M
$273.2M
Q2 24
$891.6M
$264.7M
Total Assets
AOSL
AOSL
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$1.0B
$413.2M
Q3 25
$1.0B
$432.3M
Q2 25
$1.0B
$444.3M
Q1 25
$1.1B
$489.6M
Q4 24
$1.1B
$491.1M
Q3 24
$1.1B
$477.0M
Q2 24
$1.1B
$466.8M
Debt / Equity
AOSL
AOSL
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
0.02×
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.03×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOSL
AOSL
CDNA
CDNA
Operating Cash FlowLast quarter
$-8.1M
$4.3M
Free Cash FlowOCF − Capex
$-23.1M
$514.0K
FCF MarginFCF / Revenue
-14.2%
0.4%
Capex IntensityCapex / Revenue
9.2%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$-40.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOSL
AOSL
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$-8.1M
$21.4M
Q3 25
$10.2M
$37.4M
Q2 25
$-2.8M
$9.9M
Q1 25
$7.4M
$-26.6M
Q4 24
$14.1M
$21.9M
Q3 24
$11.0M
$12.5M
Q2 24
$7.1M
$18.9M
Free Cash Flow
AOSL
AOSL
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$-23.1M
Q3 25
$420.0K
Q2 25
$-17.2M
Q1 25
$-1.1M
Q4 24
$6.6M
Q3 24
$4.1M
Q2 24
$-210.0K
FCF Margin
AOSL
AOSL
CDNA
CDNA
Q1 26
0.4%
Q4 25
-14.2%
Q3 25
0.2%
Q2 25
-9.7%
Q1 25
-0.6%
Q4 24
3.8%
Q3 24
2.3%
Q2 24
-0.1%
Capex Intensity
AOSL
AOSL
CDNA
CDNA
Q1 26
Q4 25
9.2%
Q3 25
5.4%
Q2 25
8.1%
Q1 25
5.1%
Q4 24
4.3%
Q3 24
3.8%
Q2 24
4.5%
Cash Conversion
AOSL
AOSL
CDNA
CDNA
Q1 26
1.54×
Q4 25
Q3 25
22.30×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOSL
AOSL

Power Discrete$101.0M62%
Power Ic$58.8M36%
Packaging And Testing Services$2.5M2%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons